Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.

Autor: Llaurador G; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas. Electronic address: gallaura@texaschildrens.org., Shaver K; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Wu M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Wang T; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Gillispie A; Department of Pharmacy, Texas Children's Hospital, Houston, Texas., Doherty E; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas., Craddock J; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas., Read J; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas., Yassine K; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas., Morales E; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas., George A; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas., Steffin D; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas., Krance R; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas., Martinez C; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas., Heslop H; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas., Salem B; Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, Texas.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Feb; Vol. 30 (2), pp. 217-227. Date of Electronic Publication: 2023 Nov 04.

OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL).

Autor: Ramos, C. A., Quach, D. H., Lulla, P. D., Rouce, R. H., Sharma, S., Ganesh, H. R., Nouraee, N., Briones, Y. D., Becerra‐Dominguez, L., Thakkar, S. G., Mehta, B., Perconti, S., Hsieh, E. M., Zhang, H., Grilley, B. J., Lapteva, N., Brenner, M. K., Heslop, H. E., Rooney, C. M.

Publikováno v: Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p83-85, 3p

Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.

Autor: Cornetta K; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA; Brown Center for Immunotherapy, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: kcornett@iu.edu., Yao J; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA., House K; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA., Duffy L; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA., Adusumilli PS; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Beyer R; Surgery Branch, NCI, Bethesda, MD 20892, USA., Booth C; Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK., Brenner M; Center for Cell and Gene Therapy Baylor College of Medicine, Houston TX, USA., Curran K; Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York, NY, USA; Weill Cornell Medical College, Department of Pediatrics, New York, NY, USA., Grilley B; Center for Cell and Gene Therapy Baylor College of Medicine, Houston TX, USA., Heslop H; Center for Cell and Gene Therapy Baylor College of Medicine, Houston TX, USA., Hinrichs CS; Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence, New Brunswick, NJ 08901, USA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA., Kaplan RN; Pediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD 20892, USA., Kiem HP; Fred Hutchison Cancer Center and University of Washington, Seattle, WA, USA., Kochenderfer J; Center for Cancer Research, Surgery Branch, NCI, NIH, Bethesda MD, USA., Kohn DB; Departments of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology) and Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA., Mailankody S; Myeloma and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Norberg SM; NCI, Center for Immuno-Oncology, Bethesda, MD 20892, USA., O'Cearbhaill RE; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Pappas J; Surgery Branch, NCI, Bethesda, MD 20892, USA., Park J; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ramos C; Center for Cell and Gene Therapy Baylor College of Medicine, Houston TX, USA., Ribas A; Jonsson Comprehensive Cancer Center at the University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA., Rivière I; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rosenberg SA; Surgery Branch, NCI, Bethesda, MD 20892, USA., Sauter C; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Shah NN; Pediatric Oncology Branch, Center for Cancer Research, NCI, Bethesda, MD 20892, USA., Slovin SF; Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Thrasher A; Molecular and Cellular Immunology, UCL Great Ormond Street Institute of Child Health, London, UK., Williams DA; Boston Children's Hospital, Harvard Medical School, Boston, MA, USA., Lin TY; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA; Brown Center for Immunotherapy, Indiana University School of Medicine, Indianapolis, IN, USA.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2023 Mar 01; Vol. 31 (3), pp. 801-809. Date of Electronic Publication: 2022 Dec 14.

18 - Hematopoietic Stem/Progenitor Cells and Engineering: Late Breaking Abstract: ALLOGENEIC DONOR-DERIVED CD19-CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR RELAPSED B-CELL MALIGNANCIES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

Autor: Muhsen, I.N., Cruz, H., Zhang, H., Thakkar, S.G., Grilley, B., Gee, A.P., Heslop, H., Brenner, M., Ramos, C.A.

Publikováno v: In Cytotherapy May 2022 24(5) Supplement:S27-S28

Long term follow up of subsequent malignancies in patients treated with genetically modified immune effectors

Autor: Muhsen, I.N., Steffin, D., Ahmed, N., Hegde, M., Dakhova, O., Wang, T., Wu, M., Gottschalk, S., Whittle, S., Lulla, P., Mamonkin, M., Omer, B., Rouce, R.H., Heczey, A., Metelitsa, L., Hill, L., Ramos, C.A., Rooney, C., Brenner, M., Heslop, H.

Publikováno v: In Cytotherapy May 2021 23(5) Supplement:S151-S151